Trial Profile
A retrospective study evaluating efficacy and safety of Nivolumab in African American patients with advanced or metastatic non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Oct 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 25 Oct 2018 New trial record